Taiwan Stem Cell Therapeutics (TSCT) works alongside some of Taiwan’s leading medical researchers and institutions in the regenerative medical space to develop stem-cell treatments primarily targeted at neurological disorders.
In 2020, Taiwan's government identified the Precision Medicine Initiative as a core strategic industry, with regenerative medicine as a key focus. Taiwan's leadership in regenerative medicine is attributed to a robust biotechnology industry, favorable regulatory environment, and investment in research and development. These resources provide a wealth of talent, cost-competitive R&D, and manufacturing, supported by one of the world's top-rated public health systems.
TSCT與臺灣再生醫學領域的一些領先醫學研究人員和機构合作，開發主要針對神經疾病的幹細胞治療方法。
2020年，臺灣政府把Taiwan Precision Medicine Initiative (TPMI)確定為覈心戰畧產業，再生醫學是其中一個重點。 臺灣在再生醫學方面的領先地位歸功於强大的生物技術產業、有利的監管環境以及研發投資。 這些資源提供了豐富的人才、具有成本競爭力的研發和製造，並得到了世界頂級公共衛生系統之一的支持。